SGR-1505
SGR-1505 is an orally active MALT1 allosteric inhibitor. SGR-1505 inhibits MALT1 enzymatic activity and shows anti-proliferative activity in BTK inhibitor (BTKi) -sensitive and BTKi-resistant activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines. SGR-1505 can be used for research of B-cell lymphomas[1].
Product Specifications
CAS Number
2661481-41-8
UNSPSC
12352005
Target
MALT1
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sgr-1505.html
Concentration
10mM
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
FC(F)([C@]1(C2=C(C=NC3=CC(F)=NN32)N(C1)C(NC4=CN=C(N5N=CC=N5)C(Cl)=C4)=O)C)F
Molecular Formula
C18H12ClF4N9O
Molecular Weight
481.79
References & Citations
[1]Adam Olszewski MD, et al. A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of Sgr-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies.Blood. Volume 142, Supplement 1, 2 November 2023, Page 3102.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6432947-01 0.1 mL
PRKCA (Protein Kinase C alpha, AAG6, PKCA, PRKACA, PKC-alpha, MGC129900, MGC129901) (MaxLight 405)
Sign In for Pricing
View Details MBS6432947-02 5x 0.1 mL
PRKCA (Protein Kinase C alpha, AAG6, PKCA, PRKACA, PKC-alpha, MGC129900, MGC129901) (MaxLight 405)
Sign In for Pricing
View Details 